Albiglutide Effective in Triple Therapy for Uncontrolled Type 2 Diabetes

Slideshow

In obese patients with type 2 diabetes uncontrolled by lifestyle and two oral agents, albiglutide significantly lowered A1c as part of 3-drug therapy.

HARMONY is the global phase 3 clinical trial program for albiglutide (Tanzeum), a GLP-1 receptor agonist administered once weekly by injection. HARMONY 5 evaluated the efficacy and tolerability of albiglutide in obese patients with type 2 diabetes uncontrolled on lifestyle measures and 2 oral medications. Highlights and results in the 8 slides above.

Related Videos
A panel of 5 experts on Cushing's syndrome
A panel of 5 experts on Cushing's syndrome
Laxmi Mehta, MD | Credit: American Heart Association
Reviewing 2023 with FDA Commissioner Robert M. Califf, MD
Erin Michos, MD | Credit: Johns Hopkins University
© 2024 MJH Life Sciences

All rights reserved.